CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful conscientiously but unsuccessfully to produce a single therapy, variously referred to as Pro 140, leronlimab, and Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terminology of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they will actually be used is actually an open question.

While CYDY  is actually dawdling, promote opportunities for leronlimab as a combination treatment in the treatment of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of the past several shares of mine. My first CytoDyn article, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set out the following prediction:

Rather I expect it to become a serial disappointer. CEO Pourhassan offered such a very marketing picture in the Uptick Newswire employment interview that I came away with a poor viewpoint of the business.

Irony of irony, the bad impression of mine of the business enterprise has grown steadily, though the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as prevention of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of this technology as well as associated intellectual property from Progenics to CytoDyn, as well as approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 million) as well as the very first new drug program endorsement ($5 million), and also royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with multiple indications and numerous therapies, it has this individual therapy as well as a “broad pipeline of indications” because it puts it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

The opening banner of its on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, multiple illness sorts, multiple delivering presentations in addition to multiple publications.

Can all this be smoke cigarettes and mirrors? That’s a question I have been asking myself from the very start of the interest of mine in this particular company. Judging by way of the multiples of thousands of diverse comments on listings accessible through Seeking Alpha’s CytoDyn Summary page, I’m far from alone in this particular question.

CytoDyn is a traditional battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News